Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

PET Radiotracers For Quantitative Reporter Gene Imaging

Description:

Highly sensitive PET imaging agents for quantitative tracking of gene and cell therapy  

 

Inventor

Mark Sellmyer, MD/PhD, Departmentof Radiology

Robert Mach, PhD, Departmentof Radiology

 

Problem

As gene/cell therapy becomes clinically routine, improved methods to image genetically engineered cells, including immunotherapy, are imperative. Clinicians are interested answering basic questions critical to determining response to cancer therapy such as: How many therapeutic cells are at the tumor? Is there off-target accumulation? Currently, there is no single agent that provides a facile tool for long-term cell tracking. Given the genetic manipulation inherent to gene therapy, a genetic imaging “handle” is a logical solution and positron emission tomography (PET) provides high sensitivity and spatial resolution. Standard radiotracer reporter proteins such as NIS and HSV1-tk and endogenous human receptor targets each have significant limitations.  

 

Solution

Penn researchers have developed an alternative PET imaging strategy based on E. coli dihydrofolate reductase (Ec DHFR), and isotope modifications of its specific small molecule inhibitor, trimethoprim (TMP). The bacterial DHFR binding site is different than the human binding site, resulting in 3-orders of magnitude change in TMP affinity between the two proteins, suggesting a low background in unmodified human tissues and retention in Ec DHFR in engineered cells, ultimately providing high contrast imaging. [11C]TMP can be quickly translated into patients (same molecular structure as the antibiotic) and [18F]FPTMP has a 110 minute half-life, which allows better signal to noise (can be distributed to community hospitals by a regional radiopharmacy). Using small animal models of cell tracking, 11C and 18F TMP derivatives show robust signal to noise and great potential for improving gene/cell immunotherapy.

 

Advantages

• High yield, simple, automated method of synthesis for the novel compound [18F]FPTMP, including unique linkers

• High signal-to-noise ratio

• Small, genetically portable of the transgene

• Fast track to clinical trials as the TMP parent compound is approved and widely clinically used

 

Applications

• Imagining genetically engineered cells

• Monitoring immunotherapy such as CAR-T cells or stem cell therapy such as a bone marrow transplant

• Monitoring monogenic disease therapy (gene therapy for sickle cell disease)

• Monitoring gene therapy for HIV (CCR5 modification)

 

 

Stage of Development

In vivo (mouse) data

 

Intellectual Property

Pending Provisional Application

 

Reference Media

Sellmyer et al. J Nucl Med, 2015

 

Desired partnerships

•  License

Co-development